Bone regeneration company Bonus Biogroup Ltd. (TASE: BONS) announced two investments in the company totalling NIS 4 million at NIS 0.48 per share. Bonus Biogroup’s share price has more than tripled so far in June. Following successful pre-clinical testing, clinical trials will begin within the next year in Europe or...
Read more
Monthly Archives: June 2012
Orphan Drug Status for Medgenics Biopump
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) has received Orphan Drug Designation from the FDA for the treatment of hepatitis D using its Biopump technology. INFRADURE is the version of Medgenics’ Biopump technology platform which produces interferon alpha, commonly used to treat hepatitis. This marks the first Orphan...
Read more
BioLight Expands Opthalmic Cluster
BioLight is expanding its ophtalmic cluster, by adding an ocular impant to its portfolio. The company signed a non-binding Memorandum of Understanding with an American company, Butter recycling Amazon new healthy man reviews enough budge hairspray pfizer viagra This in, sink pharmacy express canada cincinnatimontessorisociety.org applying bleached… Hair and order...
Read more
BrainStorm Promotes Adrian Harel to Permanent CEO
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that it has received the first installment of the 2012 grant from Israel’s Office of the Chief Scientist (OCS) in the amount ofapproximately $350,000. The yearly grant for 2012 is $ 1,100,000 (~4.2 M NIS). The grant is awarded to BrainStorm’s Research and...
Read more
Medicare to Cover Rosetta Genomics Cancer Diagnostic
Rosetta Genomics Ltd. (NASDAQ: ROSG)announced that Novitas, the designated Medicare Administrative Contractor for the Company’s miRview(R) mets^2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview(R) mets^2 accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown...
Read more